Satellos Bioscience Inc. Appoints Dr. Wildon Farwell as CMO for DMD Treatment Advancement
- Satellos Bioscience appointed Dr. Wildon Farwell as Chief Medical Officer to lead DMD treatment advancements starting July 16, 2025.
- Dr. Farwell brings extensive experience from Dyne Therapeutics and Biogen, crucial for navigating clinical trials for SAT-3247.
- Satellos aims to leverage its MyoRe platform under Dr. Farwell’s leadership to develop innovative therapies for muscular dystrophy.
Satellos Bioscience Appoints Dr. Wildon Farwell as Chief Medical Officer to Advance Duchenne Muscular Dystrophy Treatments
Satellos Bioscience Inc. announces the appointment of Dr. Wildon Farwell as Chief Medical Officer, effective July 16, 2025. This strategic move comes as the company gears up to initiate a Phase 2 clinical trial for SAT-3247, an investigational drug aimed at treating Duchenne muscular dystrophy (DMD). Dr. Farwell's extensive background in clinical development, particularly in neuromuscular diseases, positions him to play a vital role in advancing Satellos's mission of creating innovative therapies for serious muscle disorders.
Dr. Farwell arrives at Satellos with a robust history in the biotechnology sector, having previously served as CMO at Dyne Therapeutics. His notable contributions there include leading regulatory submissions for DMD and myotonic dystrophy type 1 therapies. His experience extends to a decade at Biogen, where he held various leadership roles, including Vice President of Late-Stage Clinical Development. Dr. Farwell's work at Biogen includes overseeing the development of SPINRAZA®, the first approved treatment for spinal muscular atrophy, showcasing his capability in bringing groundbreaking therapies to market. Such expertise is crucial as Satellos prepares to navigate the complexities of clinical trials and regulatory pathways for SAT-3247.
CEO Frank Gleeson highlights the significance of Dr. Farwell’s appointment, emphasizing that his proven track record in advancing therapeutic innovations will be instrumental as Satellos strives to develop disease-modifying treatments for DMD. Dr. Farwell succeeds Jordan Dubow, who has served as part-time CMO since January 2024 and will continue contributing in a consulting capacity. The strategic appointment also reflects Satellos's commitment to leveraging its proprietary MyoRe platform, which aims to restore muscle repair and regeneration, an essential aspect in the treatment of DMD.
In addition to his experience in clinical development, Dr. Farwell has a strong academic background, holding a medical degree from the University of Missouri and a Master of Public Health from Harvard. His previous roles include significant contributions to biomarker development and pharmacovigilance, which will be critical as the company looks to ensure the safety and efficacy of its therapies. As Satellos pushes forward with its clinical initiatives, the appointment of Dr. Farwell signifies its dedication to addressing the unmet needs in the realm of neuromuscular diseases.
Satellos Bioscience continues to focus on transforming the landscape of muscular dystrophy treatment, and with Dr. Farwell at the helm of medical affairs, the company is well-positioned to enhance its clinical strategies and forge ahead in the development of innovative therapies.
